Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently limited to 1 distinct art unit, indicating a specific technical focus for the university's active filings. This centralized activity simplifies the management of the pending intellectual property by ensuring that all communications are handled within a single USPTO division, which can lead to more efficient processing and a clearer understanding of the relevant prior art landscape.
The busiest examiner, VIJAYARAGHAVAN, JAGAMYA NMN, is responsible for 1 pending office action. With only 1 distinct examiner assigned to the portfolio, the immediate success of the university's patent applications depends on this individual. Practitioners can focus their efforts on understanding the specific examination style of this official. This high degree of concentration means that the examiner's interpretation of biotechnology patent law will be the primary factor in the university's current prosecution outcomes and overall patent strategy. Tailoring arguments to this examiner's specific technical background is essential for progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17897857 | PROMOTER OF THE TRANSCRIPTION OF NUCLEIC ACID SEQUENCE AN ITS USE | VIJAYARAGHAVAN, JAGAMYA NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17897857 | PROMOTER OF THE TRANSCRIPTION OF NUCLEIC ACID SEQUENCE AN ITS USE | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17897857 | PROMOTER OF THE TRANSCRIPTION OF NUCLEIC ACID SEQUENCE AN ITS USE | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§112 | Non-Final OA | — | Pending | Aug 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial